Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NASDAQ: SRRK) | Delayed: 41.49 -0.47 (1.12%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $41.96 | 52 Week High | $ | |||
| Open | $41.58 | 52 Week Low | $ | |||
| Day High | $41.95 | P/E | N/A | |||
| Day Low | $40.76 | EPS | $ | |||
| Volume | 1,207,203 | |||||
